RxDoctor Payments Data

Jennifer O'Dell

Family · Ooltewah, TNNPI 1407610090

Payments from drug & device makers

$3,477in general payments, 2019–2025

Across 165 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$769
  • AbbVie$529
  • Amgen$402
  • Axsome Therapeutics, Inc.$223
  • Bayer$185
  • AstraZeneca$157
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,43899%
  • Education$251%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,477 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$32,922
Medicare patients
143
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide21$23,678
EliquisApixaban17$18,358
OzempicSemaglutide14$16,577
FarxigaDapagliflozin Propanediol11$11,758
JardianceEmpagliflozin11$11,187
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,751
XareltoRivaroxaban11$7,582
Clobetasol Propionate11$2,496
Omeprazole52$697
Methylprednisolone59$488
Memantine Hcl20$479
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav34$445
Rosuvastatin Calcium44$431
Tizanidine Hcl24$410
Bupropion XlBupropion Hcl13$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$79$23,67821 claims
AstraZenecaFarxiga, Breztri Aerosphere$157$22,50822 claims
PfizerEliquis$126$18,35817 claims
Novo NordiskOzempic$769$16,57714 claims
Boehringer IngelheimJardiance$44$11,18711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Ooltewah

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →